Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer

Future Medicinal Chemistry

Volumn 4, Issue 1, 2012, Pages 107-119

  Gallick, Gary E ^a   Corn, Paul G ^a   Zurita, Amado J ^a   Lin, Sue Hwa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMUVATINIB; AVE 1642; AZD 893; AZD 8931; BEVACIZUMAB; BMS 754807; BMS 777607; BOSUTINIB; CEDIRANIB; CIXUTUMUMAB; CRIZOTINIB; DALOTUZUMAB; DASATINIB; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FORETINIB; GANITUMAB; GEFITINIB; IMATINIB; LAPATINIB; LEFLUNOMIDE; PACLITAXEL; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; SARACATINIB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SORAFENIB; SUNITINIB; TIVANTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; XL 184;

BONE METASTASIS; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 83655182199     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.161     Document Type: Review

References (149)

1. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007). (Pubitemid 46799492)
2. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5(1), 21-28 (2005). (Pubitemid 40052322)
3. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin. Cancer Res. 14(6), 1599-1602 (2008). (Pubitemid 351469442)
4. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 8(10), 568 (2011).
5. Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev. 25(4), 601-609 (2006). (Pubitemid 46071866)
6. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154(1), 293-298 (1995).
7. Knudsen BS, Gmyrek GA, Inra J et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60(6), 1113-1117 (2002). (Pubitemid 35447590)
8. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the Type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62(10), 2942-2950 (2002). (Pubitemid 34525783)
9. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 29(22), 3208-3216 (2010).
10. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22(4), 337-358 (2003). (Pubitemid 36791891)
11. Rous P. A sarcoma of the fowl transmissible by an agne separable from the tumor cells. J. Exp. Med. 13(4), 397-411 (1911).
12. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260(5547), 170-173 (1976).
13. Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl Acad. Sci. USA 77(3), 1311-1315 (1980). (Pubitemid 10072278)
14. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Ann. Rev. Cell Dev. Biol. 13, 513-609 (1997). (Pubitemid 28034534)
15. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin. Cancer Res. 12(5), 1398-1401 (2006).
16. Fizazi K. The role of Src in prostate cancer. Ann. Oncol. 18(11), 1765-1773 (2007). (Pubitemid 350119560)
17. Goldenberg-Furmanov M, Stein I, Pikarsky E et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 64(3), 1058-1066 (2004). (Pubitemid 38176910)
18. Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 68(9), 3323-3333 (2008).
19. Jensen AR, David SY, Liao C et al. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin. Cancer Res. 17(10), 3112-3122 (2011).
20. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc. Natl Acad. Sci. USA 108(16), 6579-6584 (2011).
21. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin. Cancer Res. 13(24), 7232-7236 (2007).
22. Lee YC, Huang CF, Murshed M et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22), 3196-3207 (2010).
23. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell, 64(4), 693-702 (1991). (Pubitemid 121001157)
24. Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase trial. J. Bone Miner. Res. 25(3), 463-471 (2009).
25. Lara PN J, Longmate J, Evans CP et al. A Phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20(3), 179-184 (2009).
26. Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15(23), 7421-7428 (2009).
27. Yu EY, Massard C, Gross ME et al. Once-daily dasatinib: expansion of Phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77(5), 1166-1171 (2011).
28. Araujo JC, Mathew P, Armstrong AJ et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a Phase I/II study. Cancer doi:10.1002/ cncr.26204 (2011) (Epub ahead of print).
29. Lu X, Kang Y. Epidermal growth factor signaling and bone metastasis. Br. J. Cancer 102(3), 457-461).
30. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005). (Pubitemid 40637826)
31. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1), 2-16 (2006). (Pubitemid 43199589)
32. Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the new RTK(id) on the prostate cancer block. Immunol. Endocr. Metab. Agents Med. Chem. 11(2), 131-149 (2011).
33. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141(7), 1117-1134 (2010).
34. Ibbotson KJ, Harrod J, Gowen M et al. Human recombinant transforming growth factor-a stimulates bone resorption and inhibits formation in vitro. Proc. Natl Acad. Sci. USA 83(7), 2228-2232 (1986). (Pubitemid 16020868)
35. Lorenzo JA, Quinton J, Sousa S, Raisz LG. Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures. J. Clin. Invest. 77(6), 1897-1902 (1986). (Pubitemid 16062645)
36. Takahashi N, MacDonald BR, Hon J et al. Recombinant human transforming growth factor-a stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J. Clin. Invest. 78(4), 894-898 (1986). (Pubitemid 17177067)
37. Morris MJ, Reuter VE, Kelly WK et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 94(4), 980-986 (2002).
38. Lara PN Jr, Chee KG, Longmate J et al. Trastuzumab plus docetaxel in HER-2/ neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100(10), 2125-2131 (2004). (Pubitemid 38580330)
39. Ziada A, Barqawi A, Glode LM et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; Phase II trial. Prostate 60(4), 332-337 (2004). (Pubitemid 39050653)
40. Gross M, Higano C, Pantuck A et al. A Phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7, 142 (2007).
41. Salzberg M, Rochlitz C, Morant R et al. An open-label, noncomparative Phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 30(7), 355-360 (2007). (Pubitemid 47013371)
42. de Bono JS, Bellmunt J, Attard G et al. Open-label Phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25(3), 257-262 (2007). (Pubitemid 350003013)
43. Sridhar SS, Hotte SJ, Chin JL et al. A multicenter Phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am. J. Clin. Oncol. 33(6), 609-613 (2010).
44. Lozano JJ, Soler M, Bermudo R et al. Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by factor analysis of microarray data. BMC Genomics 6, 109 (2005).
45. Cheng CJ, Ye XC, Vakar-Lopez F et al. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol. Cancer Res. 5(7), 675-684 (2007). (Pubitemid 47105486)
46. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6(5), 517-527 (2004). (Pubitemid 39469987)
47. Chen L, Siddiqui S, Bose S et al. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res. 70(14), 5994-6003 (2010).
48. Chen L, Mooso BA, Jathal MK et al. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin. Cancer Res. 17(19), 6218-6228 (2011).
49. Carver BS, Chapinski C, Wongvipat J et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell, 19(5), 575-586 (2011).
50. Soler M, Mancini F, Meca-Cortes O et al. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int. J. Cancer 125(11), 2565-2575 (2009).
51. Qi W, Cooke LS, Stejskal A et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 9, 142 (2009).
52. Hickinson DM, Klinowska T, Speake G et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2) and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 16(4), 1159-1169).
53. Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist. Updat. 8(1-2), 75-83 (2005). (Pubitemid 40797958)
54. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 15(4), 205-213 (2004). (Pubitemid 38781046)
55. Streuli CH, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem. J. 418(3), 491-506 (2009).
56. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339(8784), 23-25 (1992).
57. Rodt SA, Ahlen K, Berg A, Rubin K, Reed RK. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 495(Pt 1), 193-200 (1996). (Pubitemid 26288464)
58. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv. Cancer Res. 97, 247-274 (2007). (Pubitemid 46528991)
59. Wang Z, Kong D, Li Y, Sarkar FH. PDGF-D signaling: a novel target in cancer therapy. Curr. Drug Targets 10(1), 38-41 (2009).
60. Li H, Fredriksson L, Li X, Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 22(10), 1501-1510 (2003). (Pubitemid 36390599)
61. Ustach CV, Taube ME, Hurst NJ Jr. et al. A potential oncogenic activity of platelet-derived growth factor D in prostate cancer progression. Cancer Res. 64(5), 1722-1729 (2004). (Pubitemid 38428694)
62. Kong D, Banerjee S, Huang W et al. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res. 68(6), 1927-1934 (2008). (Pubitemid 351416579)
63. Kong D, Wang Z, Sarkar SH et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26(6), 1425-1435 (2008).
64. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the a and b receptors in prostatic intraepithelial neoplasia. Prostate 29(5), 282-286 (1996). (Pubitemid 26372600)
65. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor-a and b receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod. Pathol. 7(5), 549-554 (1994).
66. Chott A, Sun Z, Morganstern D et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am. J. Pathol. 155(4), 1271-1279 (1999). (Pubitemid 29488934)
67. Uehara H, Kim SJ, Karashima T et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl Cancer Inst. 95(6), 458-470 (2003). (Pubitemid 36432420)
68. Kim SJ, Uehara H, Yazici S et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J. Natl Cancer Inst. 98(11), 783-793 (2006). (Pubitemid 43983302)
69. Ko YJ, Small EJ, Kabbinavar F et al. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin. Cancer Res. 7(4), 800-805 (2001). (Pubitemid 32708713)
70. Mathew P, Thall PF, Jones D et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular Phase I trial in androgen-independent prostate cancer. J. Clin. Oncol. 22(16), 3323-3329 (2004). (Pubitemid 41103689)
71. Mathew P, Thall PF, Bucana CD et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin. Cancer Res. 13(19), 5816-5824 (2007). (Pubitemid 47583906)
72. Mathew P, Pisters LL, Wood CG et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J. Urol. 181(1), 81-87 (2009).
73. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298-307 (2011).
74. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935), 1306-1309 (1989). (Pubitemid 20066716)
75. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005). (Pubitemid 46202320)
76. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8(8), 632-645 (2008).
77. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28(9), 488-494 (2003).
78. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann. Intern. Med. 150(9), 595-603 (2009).
79. De S, Chen J, Narizhneva NV et al. Molecular pathway for cancer metastasis to bone. J. Biol. Chem. 278(40), 39044-39050 (2003). (Pubitemid 37221807)
80. Kitagawa Y, Dai J, Zhang J et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res. 65(23), 10921-10929 (2005). (Pubitemid 41713360)
81. Wu D, Zhau HE, Huang WC et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26(35), 5070-5077 (2007). (Pubitemid 47206947)
82. Burton JB, Priceman SJ, Sung JL et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 68(19), 7828-7837 (2008).
83. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 7(7), 1932-1936 (2001). (Pubitemid 32994827)
84. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 61(6), 2533-2536 (2001). (Pubitemid 32685834)
85. Carlevaro MF, Cermelli S, Cancedda R, Descalzi Cancedda F. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J. Cell Sci. 113(Pt 1), 59-69 (2000). (Pubitemid 30066333)
86. Street J, Bao M, deGuzman L et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl Acad. Sci. USA 99(15), 9656-9661 (2002). (Pubitemid 34831103)
87. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. Development 131(9), 2161-2171 (2004). (Pubitemid 38702047)
88. Mayr-Wohlfart U, Waltenberger J, Hausser H et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 30(3), 472-477 (2002). (Pubitemid 34204121)
89. Matsumoto Y, Tanaka K, Hirata G et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J. Immunol. 168(11), 5824-5831 (2002). (Pubitemid 34556170)
90. Niida S, Kaku M, Amano H et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190(2), 293-298 (1999). (Pubitemid 29354921)
91. Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a Phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 103(12), 1636-1640 (2009).
92. Ryan CJ, Stadler WM, Roth B et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest. New Drugs 25(5), 445-451 (2007). (Pubitemid 47222908)
93. Ward JE, Karrison T, Chatta G et al. A randomized, Phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2011.49 (2011) (Epub ahead of print).
94. Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 20(5), 913-920 (2009).
95. Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 21(2), 319-324 (2009).
96. Zurita AJ, George DJ, Shore ND et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a Phase I/II clinical trial. Ann. Oncol. doi:10.1093/annonc/mdr349 (2011) (Epub ahead of print).
97. Zurita AJ, Ward JF, Araujo JC et al. Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients with localized prostate cancer (PCa) at high risk for recurrence. J. Clin. Oncol. 29(Suppl. 7), (2011) (Abstract 143).
98. Dror-Michaelson M, Oudard S, Ou Y et al. Randomized, placebo-controlled, Phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 4515).
99. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol. 28(33), 4985-4995 (2010).
100. Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 80(8), 1115-1124 (2010).
101. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505-518 (2004). (Pubitemid 38868620)
102. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 61(20), 7388-7393 (2001). (Pubitemid 32995021)
103. Kimura T, Kuwata T, Ashimine S et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin. Cancer Res. 16(1), 121-129 (2009)
104. Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P, Koutsilieris M. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol. Med. 14(7-8), 403-411 (2008).
105. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144(6), 2319-2324 (2003). (Pubitemid 36629883)
106. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology 141(6), 2257-2265 (2000). (Pubitemid 32274381)
107. Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63(16), 5073-5083 (2003). (Pubitemid 37022647)
108. Krueckl SL, Sikes RA, Edlund NM et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res. 64(23), 8620-8629 (2004). (Pubitemid 39552075)
109. Wu JD, Odman A, Higgins LM et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin. Cancer Res. 11(8), 3065-3074 (2005). (Pubitemid 40525213)
110. Scartozzi M, Bianconi M, Maccaroni E et al. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discov. Med. 11(57), 144-153 (2011).
111. Ryan CJ, Harzstark AH, Rosenberg J et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 101(4), 436-439 (2008). (Pubitemid 351160938)
112. Friedlander TW, Weinberg VK, Huang Y et al. A Phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with nonmetastatic hormone-sensitive prostate cancer. Oncol. Rep. doi:10.3892/or.2011.1487 (2011) (Epub ahead of print).
113. Carboni JM, Wittman M, Yang Z et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8(12), 3341-3349 (2009).
114. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv. Cancer Res. 91, 31-67 (2004). (Pubitemid 39140956)
115. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig. Drugs 17(7), 997-1011 (2008).
116. Trusolino L, Bertotti A, Comoglio PM. MET signaling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell. Biol. 11(12), 834-848 (2010).
117. Bottaro DP, Rubin JS, Faletto DL et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251(4995), 802-804 (1991). (Pubitemid 21926175)
118. Hurle RA, Davies G, Parr C et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol. Histopathol. 20(4), 1339-1349 (2005). (Pubitemid 41489177)
119. Nakamura T, Sakai K, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J. Gastroenterol. Hepatol. 26(Suppl. 1), 188-202 (2011).
120. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell. Biol. 9(8), 628-638 (2008).
121. van Leenders GJ, Gage WR, Hicks JL et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am. J. Pathol. 162(5), 1529-1537 (2003). (Pubitemid 36512835)
122. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67(3), 967-975 (2007).
123. Russo AL, Jedlicka K, Wernick M et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin. Cancer Res. 15(13), 4292-4298 (2009).
124. Gmyrek GA, Walburg M, Webb CP et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am. J. Pathol. 159(2), 579-590 (2001). (Pubitemid 32751088)
125. Humphrey PA, Zhu X, Zarnegar R et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147(2), 386-396 (1995).
126. Yasuda K, Nagakawa O, Akashi T et al. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 69(4), 346-351 (2009).
127. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol. Cancer Ther. 9(6), 1554-1561 (2010).
128. Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 10, 556 (2010).
129. Qian F, Engst S, Yamaguchi K et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69(20), 8009-8016 (2009)
130. Eder JP, Shapiro GI, Appleman LJ et al. A Phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16(13), 3507-3516 (2010).
131. Adjei AA, Schwartz B, Garmey E. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 16(6), 788-799 (2011).
132. Yap TA, Olmos D, Brunetto AT et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 29(10), 1271-1279 (2011).
133. Smith DC, Spira A, De Grève J et al. Phase II Study of XL184 in a cohort of patients with castration resistant prostate cancer and measurable soft tissue disease. Presented at: The 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 16-19 November, Berlin, Germany (2010).
134. Hussain M, Smith MR, Sweeney C et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a Phase II randomized discontinuation trial. J. Clin. Oncol. 29(Suppl.), (2011) (Abstract 4516).
135. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem. J. 437(2), 199-213 (2011).
136. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60, 1-41 (1993).
137. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16(2), 139-149 (2005). (Pubitemid 40616112)
138. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis-new insights into epithelial-stromal interactions. Cancer Cell 12(6), 495-497 (2007). (Pubitemid 350199077)
139. Thomson AA, Cunha GR. Prostatic growth and development are regulated by FGF10. Development 126(16), 3693-3701 (1999). (Pubitemid 29419524)
140. Lin Y, Liu G, Zhang Y et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 134(4), 723-734 (2007). (Pubitemid 46437914)
141. Memarzadeh S, Xin L, Mulholland DJ et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12(6), 572-585 (2007). (Pubitemid 350199069)
142. Acevedo VD, Gangula RD, Freeman KW et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12(6), 559-571 (2007). (Pubitemid 350199071)
143. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 8(4), 580-588 (2009).
144. Li ZG, Mathew P, Yang J et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 118(8), 2697-2710 (2008).
145. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8(3), 235-253 (2009).
146. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol. Ther. 125(1), 105-117 (2009).
147. Mahajan K, Mahajan NP. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J. Cell Physiol. 224(2), 327-333 (2010).
148. Mahajan NP, Liu Y, Majumder S et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl Acad. Sci. USA 104(20), 8438-8443 (2007). (Pubitemid 47175506)
149. Mahajan K, Challa S, Coppola D et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 70(12), 1274-1285 (2010).